DelveInsight's "Cytomegalovirus Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and ...

Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...

− If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population − CMV is one of the most common infections experienced by transplant recipients ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first ...

The US Food and Drug Administration (FDA) has approved the first treatment for post-transplant cytomegalovirus (CMV) that is resistant to other drugs. The treatment, maribavir (Livtencity), is ...

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a ...

Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, ...

Credit: Getty Images This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.

“Why didn’t anyone tell me about this virus?” is a frequent response I hear from parents upon learning their newborn is infected with cytomegalovirus or CMV. Although more than half of the U.S.

In August 2019, when Corey Clem was pregnant with her daughter, she caught a cold with a “pretty bad cough,” she told TODAY. She visited her doctor to make sure everything was OK and received a ...